<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03441633</url>
  </required_header>
  <id_info>
    <org_study_id>B0661076</org_study_id>
    <secondary_id>SPAF</secondary_id>
    <nct_id>NCT03441633</nct_id>
  </id_info>
  <brief_title>Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)</brief_title>
  <acronym>SPAF</acronym>
  <official_title>APIXABAN DRUG UTILIZATION STUDY IN STROKE PREVENTION IN ATRIAL FIBRILLATION (SPAF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Apixaban is a direct anticoagulant, which inhibits the factor Xa. Its clinical efficiency in
      prevention of stroke and systemic embolism in adult patients with NVAF (non/valvular atrial
      fibrillation) was demonstrated as well as has shown better safety profile compared with
      warfarin. A Drug Utilization study will evaluate whether this drug has been used in
      accordance with the approved indication and recommendations described in the summary of
      product characteristics (SmPC) and estimate possible misuse or overuse apixaban.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary research question is to evaluate the apixaban utilization according to the
      approved SPAF indication and recommendations by EMA.

      In addition a comparison with a cohort of NVAF patients treated with VKA, dabigatran and
      rivaroxaban for the SPAF indication will also be performed.

      Objective 1: To characterize patients using apixaban according to demographics, comorbidity,
      risk of thromboembolic events (CHADS2 and CHA2DS2-Vasc scores), risk of bleeding events
      (HAS-BLED score), comedications and compare it with the profile of patients treated with VKA,
      dabigatran and rivaroxaban.

      Objective 2: Describe the level of appropriate usage according to the posology recommended in
      the apixaban SmPC.

      Objective 3: Describe the potential interactions with other drugs prescribed concomintatly
      according with the SmPC recommendations.

      Objective 4: Estimate the level of apixaban adherence by the medication possession ratio
      (MPR) and discontinuation rates and compare it with VKA, dabigatran and rivaroxaban cohort.

      Objective 5: To analyze INR (International Normalized Ratio) values during the last 12 months
      and to obtain TTR (Time in Therapeutic Range) values in patients previously treated with VKA,
      and during the whole study period for those in the cohort treated with VKA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 18, 2016</start_date>
  <completion_date type="Actual">March 8, 2017</completion_date>
  <primary_completion_date type="Actual">March 8, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants by Their Sociodemographic Characteristics: Smoking Habit</measure>
    <time_frame>Day 1</time_frame>
    <description>Socio-demographics were characteristics of a population. One of the socio-demographics characteristics included smoking habit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants by Their Sociodemographic Characteristics: Alcoholic Habit</measure>
    <time_frame>Day 1</time_frame>
    <description>Socio-demographics were characteristics of a population. One of the socio-demographics characteristics included alcoholic habit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants by Their Sociodemographic Characteristics: MEDEA</measure>
    <time_frame>Day 1</time_frame>
    <description>Socio-demographics were characteristics of a population. One of the socio-demographics characteristics included MEDEA. MEDEA was a deprivation index that was associated with overall mortality in urban areas. It included factors like job, education, housing conditions and single parent homes. The MEDEA index was categorized in quintiles for urban areas, with quintile 1 corresponding to the least deprived population and quintile 5, the most deprived.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants by Their Sociodemographic Characteristics: Body Mass Index (BMI)</measure>
    <time_frame>Day 1</time_frame>
    <description>Socio-demographics were characteristics of a population. One of the socio-demographics characteristics included BMI. BMI was defined as an index for assessing overweight and underweight and was obtained by dividing body weight in kilograms (kg) by height in meters squared (m^2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants by Comorbidity</measure>
    <time_frame>Up to 12 months after date of first prescription</time_frame>
    <description>Comorbidity was defined as the presence of one or more additional diseases or disorders co-occurring with (that is, concomitant or concurrent with) a primary disease or disorder.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk of Bleeding Events: HAS-BLED Score</measure>
    <time_frame>Up to 12 months prior to enrollment</time_frame>
    <description>Risk of bleeding events was assessed by using HAS-BLED score. HAS-BLED was a scoring system that was developed to assess 1 year risk of occurrence of major hemorrhage. HAS-BLED score was assessed by combining score of 9 risk factors: hypertension history, renal disease, liver disease, stroke history, prior major bleeding or predisposition to bleeding, labile international normalized ratio (INR), age &gt;65 years, medication usage predisposing to bleeding and alcohol or drug usage history. The total score ranged from 0 to 9 where 0 = low risk of bleed per 100 participants-year and &gt;3 = high risk of bleed per 100 participants-year.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk of Thromboembolic Events: CHADS2 Score</measure>
    <time_frame>Up to 12 months prior to enrollment</time_frame>
    <description>Thromboembolic events were defined as an embolic stroke that occurred when a blood clot that formed elsewhere in the body breaks loose and travels to the brain via bloodstream. Risk of thromboembolic events was calculated using CHADS2 score. CHADS2 score was assessed by combining score of 5 risk factors (congestive heart failure history, hypertension history, age &gt;=75 years, diabetes mellitus history and stroke/transient ischemic attack symptoms previously). Total CHADS2 score ranged from 0-6 where 0 =low risk and 6 =high risk of stroke.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk of Thromboembolic Events: CHA2DS2Vasc Score</measure>
    <time_frame>Up to 12 months prior to enrollment</time_frame>
    <description>Thromboembolic events were defined as an embolic stroke that occurred when a blood clot that formed elsewhere in the body breaks loose and travels to the brain via bloodstream. Risk of thromboembolic events was calculated using CHA2DS2Vasc score. CHA2DS2Vasc score was assessed by combining score of 8 risk factors (female, &gt;=65 and &lt;75 years, congestive heart failure history, hypertension history, diabetes mellitus history, vascular disease history, age &gt;=75 years and stroke/TIA symptoms previously). Total CHA2DS2Vasc score ranged from 0-9 where 0=low risk and 9=high risk of stroke.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants by Comedications</measure>
    <time_frame>Up to 30 days after date of first prescription</time_frame>
    <description>Comedication was defined as the second or alternative medication used to relieve the side-effects of another medicine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Apixaban Adherence With VKA, Dabigatran and Rivaroxaban as Assessed by Medication Possession Ratio (MPR)</measure>
    <time_frame>Up to 12 months after date of first prescription</time_frame>
    <description>MPR was one of the methods of measuring adherence and was defined as the ratio of all days supply to elapsed days, during the 12-month observation period. All days supply defined as sum of number of days supply between the start date and last prescription dispensed. Elapsed days defined as number of days between the start date and the last prescription dispensed. There were three categories of adherence: poor defined as &lt;80% of MPR, good defined as between 80% and 120% of MPR and over adherence defined as &gt;120% of MPR.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Apixaban Adherence With VKA, Dabigatran and Rivaroxaban as Assessed by Discontinuation Throughout the Year</measure>
    <time_frame>Up to 12 months after date of first prescription</time_frame>
    <description>Discontinuation rate was defined as the lack of subsequent prescription of the index drugs within 2 months after last supply day of the last prescription. It was analyzed by calculating the treatment withdrawal or switch rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apixaban Adherence With VKA, Dabigatran and Rivaroxaban by Number of Defined Daily Dose (NDDD)</measure>
    <time_frame>Up to 12 months after date of first prescription</time_frame>
    <description>NDDD was a measure that represented the average daily maintenance dose for the main indication of a drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>International Normalized Ratio (INR) Values During the Last 12 Months Values in Participants Previously Treated With VKA</measure>
    <time_frame>Up to 12 months after date of first prescription</time_frame>
    <description>INR was defined as the ratio of the participant's prothrombin time and the normal mean prothrombin time. Prothrombin time defined as a time taken by the blood to clot in participants receiving oral anticoagulant medication. INR was categorized according to the risk level: risk for coagulation (INR&lt;2); optimal range (2&lt;INR&lt;3); and risk of hemorrhages (INR&gt;3).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time in Therapeutic Range (TTR) Values During the Last 12 Months Values in Participants Previously Treated With VKA</measure>
    <time_frame>Up to 12 months after date of first prescription</time_frame>
    <description>TTR was defined as the duration of time in which the participant's INR values were within a desired range (2 to 3). INR was defined as the ratio of the participant's prothrombin time and the normal mean prothrombin time. Prothrombin time defined as a time taken by the blood to clot in participants receiving oral anticoagulant medication. INR was categorized according to the risk level: risk for coagulation (INR&lt;2); optimal range (2&lt;INR&lt;3); and risk of hemorrhages (INR&gt;3).</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">51690</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Group 1. Apixaban</arm_group_label>
    <description>Patients who are on treatment with apixaban.
1a. patients who have initiated with apixaban as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).
1b. patients who previously have been treated with VKA in the 12 months before index date.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2. VKA</arm_group_label>
    <description>Patients who are on treatment with VKA.
2a. patients who have initiated with VKA as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).
2b. patients who previously have been treated with VKA in the 12 months before index date.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3. Dabigatran</arm_group_label>
    <description>Patients who are on treatment with dabigatran.
3a. patients who have initiated with dabigatran as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).
3b. patients who previously have been treated with VKA in the 12 months before index date.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4. Rivaroxaban</arm_group_label>
    <description>Patients who are on treatment with rivaroxaban.
4a. patients who have initiated with rivaroxaban as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).
4b. patients who previously have been treated with VKA in the 12 months before index date.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>apixaban</intervention_name>
    <description>current or new medication</description>
    <arm_group_label>Group 1. Apixaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran</intervention_name>
    <description>current or new medication</description>
    <arm_group_label>Group 3. Dabigatran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VKA</intervention_name>
    <description>current or new medication</description>
    <arm_group_label>Group 2. VKA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rivaroxaban</intervention_name>
    <description>current or new medication</description>
    <arm_group_label>Group 4. Rivaroxaban</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        SIDIAP currently collects information from 274 primary health care centers, including more
        than 5.8 million patients, about 80 % of the Catalonia population, or more than 10 % of the
        Spanish population covered by the Catalan Institute of Health.

        The study population for these cohorts includes all eligible subjects from the source
        population with a first -recorded prescription of apixaban VKA, dabigatran or rivaroxaban
        for the SPAF indication, registered in SIDIAP database and diagnosis of NVAF for study
        period.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients more than 18 years-old.

          2. Patients diagnosed with NVAF registered in primary care according to ICD-10.

          3. Patients initiating apixaban (naïve or VKA experienced), VKA (naïve or VKA
             experienced), dabigatran or rivaroxaban for the SPAF indication.

          4. Continuous enrolment in the 12 months pre-index.

        Exclusion Criteria:

          1. Patients with valvular heart disease (ICD 10: I05.0-I05.09, I08.0-I08.9) including
             patients with mitral prosthetic valves.

          2. Lost to follow-up (e.g. transfer to primary care center non-ICS).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IDIAP Jordi Gol</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>8007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B0661076&amp;StudyName=APIXABAN+DRUG+UTILIZATION+STUDY+IN+STROKE+PREVENTION+IN+ATRIAL+FIBRILLATION+%28SPAF%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>February 2, 2018</study_first_submitted>
  <study_first_submitted_qc>February 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2018</study_first_posted>
  <results_first_submitted>February 23, 2018</results_first_submitted>
  <results_first_submitted_qc>January 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 19, 2019</results_first_posted>
  <last_update_submitted>January 15, 2019</last_update_submitted>
  <last_update_submitted_qc>January 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>apixaban</keyword>
  <keyword>stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 7, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT03441633/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Apixaban: Naive</title>
          <description>Participants who were treated with apixaban without prior prescription of vitamin K antagonists (VKA) (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date (when the participant took the drug for the first time). The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="P2">
          <title>Apixaban: Non Naive</title>
          <description>Participants who were treated with apixaban with prior prescription of VKA (warfarin or acenocoumarol), dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="P3">
          <title>Acenocoumarol: Naive</title>
          <description>Participants who were treated with acenocoumarol without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="P4">
          <title>Acenocoumarol: Non-Naive</title>
          <description>Participants who were treated with acenocoumarol with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="P5">
          <title>Warfarin: Naive</title>
          <description>Participants who were treated with warfarin without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="P6">
          <title>Warfarin: Non-Naive</title>
          <description>Participants who were treated with warfarin with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="P7">
          <title>Dabigatran: Naive</title>
          <description>Participants who were treated with dabigatran without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="P8">
          <title>Dabigatran: Non-Naive</title>
          <description>Participants who were treated with dabigatran with prior prescription of VKA (warfarin or acenocoumarol), apixaban or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="P9">
          <title>Rivaroxaban: Naive</title>
          <description>Participants who were treated with rivaroxaban without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="P10">
          <title>Rivaroxaban: Non-Naive</title>
          <description>Participants who were treated with rivaroxaban with prior prescription of VKA (warfarin or acenocoumarol), apixaban and dabigatran in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4712"/>
                <participants group_id="P2" count="1423"/>
                <participants group_id="P3" count="32212"/>
                <participants group_id="P4" count="192"/>
                <participants group_id="P5" count="2286"/>
                <participants group_id="P6" count="363"/>
                <participants group_id="P7" count="2855"/>
                <participants group_id="P8" count="953"/>
                <participants group_id="P9" count="5132"/>
                <participants group_id="P10" count="1562"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4712"/>
                <participants group_id="P2" count="1423"/>
                <participants group_id="P3" count="32212"/>
                <participants group_id="P4" count="192"/>
                <participants group_id="P5" count="2286"/>
                <participants group_id="P6" count="363"/>
                <participants group_id="P7" count="2855"/>
                <participants group_id="P8" count="953"/>
                <participants group_id="P9" count="5132"/>
                <participants group_id="P10" count="1562"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Study population included all participants with a first-recorded prescription of apixaban, VKA, dabigatran or rivaroxaban for stroke prevention in atrial fibrillation(SPAF) registered in information system for the improvement of research in primary care(SIDIAP) database during the study and diagnosed with non-valvular atrial fibrillation(NVAF).</population>
      <group_list>
        <group group_id="B1">
          <title>Apixaban: Naive</title>
          <description>Participants who were treated with apixaban without prior prescription of vitamin K antagonists (VKA) (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date (when the participant took the drug for the first time). The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="B2">
          <title>Apixaban: Non Naive</title>
          <description>Participants who were treated with apixaban with prior prescription of VKA (warfarin or acenocoumarol), dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="B3">
          <title>Acenocoumarol: Naive</title>
          <description>Participants who were treated with acenocoumarol without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="B4">
          <title>Acenocoumarol: Non-Naive</title>
          <description>Participants who were treated with acenocoumarol with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="B5">
          <title>Warfarin: Naive</title>
          <description>Participants who were treated with warfarin without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="B6">
          <title>Warfarin: Non Naive</title>
          <description>Participants who were treated with warfarin with prior prescription of different VKA, apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="B7">
          <title>Dabigatran: Naive</title>
          <description>Participants who were treated with dabigatran without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="B8">
          <title>Dabigatran: Non-Naive</title>
          <description>Participants who were treated with dabigatran with prior prescription of VKA (warfarin or acenocoumarol), apixaban or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="B9">
          <title>Rivaroxaban: Naive</title>
          <description>Participants who were treated with rivaroxaban without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="B10">
          <title>Rivaroxaban: Non-Naive</title>
          <description>Participants who were treated with rivaroxaban with prior prescription of VKA (warfarin or acenocoumarol), apixaban and dabigatran in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4712"/>
            <count group_id="B2" value="1423"/>
            <count group_id="B3" value="32212"/>
            <count group_id="B4" value="192"/>
            <count group_id="B5" value="2286"/>
            <count group_id="B6" value="363"/>
            <count group_id="B7" value="2855"/>
            <count group_id="B8" value="953"/>
            <count group_id="B9" value="5132"/>
            <count group_id="B10" value="1562"/>
            <count group_id="B11" value="51690"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4712"/>
                    <count group_id="B2" value="1423"/>
                    <count group_id="B3" value="32212"/>
                    <count group_id="B4" value="192"/>
                    <count group_id="B5" value="2286"/>
                    <count group_id="B6" value="363"/>
                    <count group_id="B7" value="2855"/>
                    <count group_id="B8" value="953"/>
                    <count group_id="B9" value="5132"/>
                    <count group_id="B10" value="1562"/>
                    <count group_id="B11" value="51690"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.8" spread="11.1"/>
                    <measurement group_id="B2" value="78.1" spread="8.7"/>
                    <measurement group_id="B3" value="73.5" spread="12.3"/>
                    <measurement group_id="B4" value="74.6" spread="10.7"/>
                    <measurement group_id="B5" value="69.7" spread="13.4"/>
                    <measurement group_id="B6" value="74.9" spread="12.9"/>
                    <measurement group_id="B7" value="69.9" spread="12.3"/>
                    <measurement group_id="B8" value="76.5" spread="9.5"/>
                    <measurement group_id="B9" value="69.3" spread="13.2"/>
                    <measurement group_id="B10" value="76.4" spread="10.5"/>
                    <measurement group_id="B11" value="72.8" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4712"/>
                    <count group_id="B2" value="1423"/>
                    <count group_id="B3" value="32212"/>
                    <count group_id="B4" value="192"/>
                    <count group_id="B5" value="2286"/>
                    <count group_id="B6" value="363"/>
                    <count group_id="B7" value="2855"/>
                    <count group_id="B8" value="953"/>
                    <count group_id="B9" value="5132"/>
                    <count group_id="B10" value="1562"/>
                    <count group_id="B11" value="51690"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2661"/>
                    <measurement group_id="B2" value="751"/>
                    <measurement group_id="B3" value="15531"/>
                    <measurement group_id="B4" value="94"/>
                    <measurement group_id="B5" value="979"/>
                    <measurement group_id="B6" value="205"/>
                    <measurement group_id="B7" value="1399"/>
                    <measurement group_id="B8" value="479"/>
                    <measurement group_id="B9" value="2649"/>
                    <measurement group_id="B10" value="811"/>
                    <measurement group_id="B11" value="25559"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2051"/>
                    <measurement group_id="B2" value="672"/>
                    <measurement group_id="B3" value="16681"/>
                    <measurement group_id="B4" value="98"/>
                    <measurement group_id="B5" value="1307"/>
                    <measurement group_id="B6" value="158"/>
                    <measurement group_id="B7" value="1456"/>
                    <measurement group_id="B8" value="474"/>
                    <measurement group_id="B9" value="2483"/>
                    <measurement group_id="B10" value="751"/>
                    <measurement group_id="B11" value="26131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants by Their Sociodemographic Characteristics: Smoking Habit</title>
        <description>Socio-demographics were characteristics of a population. One of the socio-demographics characteristics included smoking habit.</description>
        <time_frame>Day 1</time_frame>
        <population>Study population included all participants with a first-recorded prescription of apixaban, VKA, dabigatran or rivaroxaban for SPAF registered in SIDIAP database during the study and diagnosed with NVAF.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban: Naive</title>
            <description>Participants who were treated with apixaban without prior prescription of vitamin K antagonists (VKA) (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date (when the participant took the drug for the first time). The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Apixaban: Non Naive</title>
            <description>Participants who were treated with apixaban with prior prescription of VKA (warfarin or acenocoumarol), dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O3">
            <title>Acenocoumarol: Naive</title>
            <description>Participants who were treated with acenocoumarol without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O4">
            <title>Acenocoumarol: Non-Naive</title>
            <description>Participants who were treated with acenocoumarol with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O5">
            <title>Warfarin: Naive</title>
            <description>Participants who were treated with warfarin without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O6">
            <title>Warfarin: Non-Naive</title>
            <description>Participants who were treated with warfarin with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O7">
            <title>Dabigatran: Naive</title>
            <description>Participants who were treated with dabigatran without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O8">
            <title>Dabigatran: Non-Naive</title>
            <description>Participants who were treated with dabigatran with prior prescription of VKA (warfarin or acenocoumarol), apixaban or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O9">
            <title>Rivaroxaban: Naive</title>
            <description>Participants who were treated with rivaroxaban without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O10">
            <title>Rivaroxaban: Non-Naive</title>
            <description>Participants who were treated with rivaroxaban with prior prescription of VKA (warfarin or acenocoumarol), apixaban and dabigatran in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants by Their Sociodemographic Characteristics: Smoking Habit</title>
          <description>Socio-demographics were characteristics of a population. One of the socio-demographics characteristics included smoking habit.</description>
          <population>Study population included all participants with a first-recorded prescription of apixaban, VKA, dabigatran or rivaroxaban for SPAF registered in SIDIAP database during the study and diagnosed with NVAF.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4712"/>
                <count group_id="O2" value="1423"/>
                <count group_id="O3" value="32212"/>
                <count group_id="O4" value="192"/>
                <count group_id="O5" value="2286"/>
                <count group_id="O6" value="363"/>
                <count group_id="O7" value="2855"/>
                <count group_id="O8" value="953"/>
                <count group_id="O9" value="5132"/>
                <count group_id="O10" value="1562"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="1844"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="112"/>
                    <measurement group_id="O6" value="14"/>
                    <measurement group_id="O7" value="225"/>
                    <measurement group_id="O8" value="23"/>
                    <measurement group_id="O9" value="354"/>
                    <measurement group_id="O10" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-smoker</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3104"/>
                    <measurement group_id="O2" value="946"/>
                    <measurement group_id="O3" value="19440"/>
                    <measurement group_id="O4" value="119"/>
                    <measurement group_id="O5" value="1166"/>
                    <measurement group_id="O6" value="234"/>
                    <measurement group_id="O7" value="1684"/>
                    <measurement group_id="O8" value="623"/>
                    <measurement group_id="O9" value="3079"/>
                    <measurement group_id="O10" value="1030"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Ex-smoker</title>
                  <measurement_list>
                    <measurement group_id="O1" value="459"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="3676"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="320"/>
                    <measurement group_id="O6" value="26"/>
                    <measurement group_id="O7" value="355"/>
                    <measurement group_id="O8" value="72"/>
                    <measurement group_id="O9" value="608"/>
                    <measurement group_id="O10" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Smoker</title>
                  <measurement_list>
                    <measurement group_id="O1" value="942"/>
                    <measurement group_id="O2" value="371"/>
                    <measurement group_id="O3" value="7252"/>
                    <measurement group_id="O4" value="50"/>
                    <measurement group_id="O5" value="688"/>
                    <measurement group_id="O6" value="89"/>
                    <measurement group_id="O7" value="591"/>
                    <measurement group_id="O8" value="235"/>
                    <measurement group_id="O9" value="1091"/>
                    <measurement group_id="O10" value="392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in naive participants (Non-smoker)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in naive participants (Ex-smoker)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.14</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in naive participants (Smoker)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in non-naive participants (Non-smoker)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.755</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in non-naive participants (Ex-smoker)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.426</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in non-naive participants (Smoker)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.930</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in naive participants (Non-smoker)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in naive participants (Ex-smoker)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in naive participants (Smoker)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in non-naive participants (Non-smoker)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.755</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in non-naive participants (Ex-smoker)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.426</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in non-naive participants (Smoker)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.930</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in naive participants (Non-smoker)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in naive participants (Ex-smoker)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.08</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in naive participants (Smoker)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.08</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in non-naive participants (Non-smoker)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.755</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in non-naive participants (Ex-smoker)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.426</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>2.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in non-naive participants (Smoker)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.930</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in naive participants (Non-smoker)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in naive participants (Ex-smoker)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.29</ci_lower_limit>
            <ci_upper_limit>1.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in naive participants (Smoker)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.54</ci_lower_limit>
            <ci_upper_limit>1.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in non-naive participants (Non-smoker)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.755</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in non-naive participants (Ex-smoker)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.426</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in naive participants (Smoker)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.930</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants by Their Sociodemographic Characteristics: Alcoholic Habit</title>
        <description>Socio-demographics were characteristics of a population. One of the socio-demographics characteristics included alcoholic habit.</description>
        <time_frame>Day 1</time_frame>
        <population>Study population included all participants with a first-recorded prescription of apixaban, VKA, dabigatran or rivaroxaban for SPAF registered in SIDIAP database during the study and diagnosed with NVAF.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban: Naive</title>
            <description>Participants who were treated with apixaban without prior prescription of vitamin K antagonists (VKA) (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date (when the participant took the drug for the first time). The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Apixaban: Non Naive</title>
            <description>Participants who were treated with apixaban with prior prescription of VKA (warfarin or acenocoumarol), dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O3">
            <title>Acenocoumarol: Naive</title>
            <description>Participants who were treated with acenocoumarol without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O4">
            <title>Acenocoumarol: Non-Naive</title>
            <description>Participants who were treated with acenocoumarol with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O5">
            <title>Warfarin: Naive</title>
            <description>Participants who were treated with warfarin without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O6">
            <title>Warfarin: Non-Naive</title>
            <description>Participants who were treated with warfarin with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O7">
            <title>Dabigatran: Naive</title>
            <description>Participants who were treated with dabigatran without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O8">
            <title>Dabigatran: Non-Naive</title>
            <description>Participants who were treated with dabigatran with prior prescription of VKA (warfarin or acenocoumarol), apixaban or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O9">
            <title>Rivaroxaban: Naive</title>
            <description>Participants who were treated with rivaroxaban without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O10">
            <title>Rivaroxaban: Non-Naive</title>
            <description>Participants who were treated with rivaroxaban with prior prescription of VKA (warfarin or acenocoumarol), apixaban and dabigatran in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants by Their Sociodemographic Characteristics: Alcoholic Habit</title>
          <description>Socio-demographics were characteristics of a population. One of the socio-demographics characteristics included alcoholic habit.</description>
          <population>Study population included all participants with a first-recorded prescription of apixaban, VKA, dabigatran or rivaroxaban for SPAF registered in SIDIAP database during the study and diagnosed with NVAF.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4712"/>
                <count group_id="O2" value="1423"/>
                <count group_id="O3" value="32212"/>
                <count group_id="O4" value="192"/>
                <count group_id="O5" value="2286"/>
                <count group_id="O6" value="363"/>
                <count group_id="O7" value="2855"/>
                <count group_id="O8" value="953"/>
                <count group_id="O9" value="5132"/>
                <count group_id="O10" value="1562"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2162"/>
                    <measurement group_id="O2" value="353"/>
                    <measurement group_id="O3" value="11299"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="839"/>
                    <measurement group_id="O6" value="91"/>
                    <measurement group_id="O7" value="1263"/>
                    <measurement group_id="O8" value="211"/>
                    <measurement group_id="O9" value="2475"/>
                    <measurement group_id="O10" value="366"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No intake</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1749"/>
                    <measurement group_id="O2" value="810"/>
                    <measurement group_id="O3" value="14337"/>
                    <measurement group_id="O4" value="111"/>
                    <measurement group_id="O5" value="984"/>
                    <measurement group_id="O6" value="212"/>
                    <measurement group_id="O7" value="1054"/>
                    <measurement group_id="O8" value="550"/>
                    <measurement group_id="O9" value="1696"/>
                    <measurement group_id="O10" value="923"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate intake</title>
                  <measurement_list>
                    <measurement group_id="O1" value="765"/>
                    <measurement group_id="O2" value="247"/>
                    <measurement group_id="O3" value="6241"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="447"/>
                    <measurement group_id="O6" value="58"/>
                    <measurement group_id="O7" value="505"/>
                    <measurement group_id="O8" value="187"/>
                    <measurement group_id="O9" value="915"/>
                    <measurement group_id="O10" value="255"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Risk consumption</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="335"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="33"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="46"/>
                    <measurement group_id="O10" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in naive participants (No intake)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in naive participants (Moderate intake)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in naive participants (Risk consumption)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.164</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>2.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in non-naive participants (No intake)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.826</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in non-naive participants (Moderate intake)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.190</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in non-naive participants (Risk consumption)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.526</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in naive participants (No intake)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in naive participants (Moderate intake)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in naive participants (Risk consumption)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.164</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in non-naive participants (No intake)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.826</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in non-naive participants (Moderate intake)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.190</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in non-naive participants (Risk consumption)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.526</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>2.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in naive participants (No intake)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.28</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in naive participants (Moderate intake)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.14</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in naive participants (Risk consumption)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.164</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in non-naive participants (No intake)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.826</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in non-naive participants (Moderate intake)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.190</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in non-naive participants (Risk consumption)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.526</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>4.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in naive participants (No intake)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.16</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in naive participants (Moderate intake)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in naive participants (Risk consumption)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.164</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>1.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in non-naive participants (No intake)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.826</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in non-naive participants (Moderate intake)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.190</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in non-naive participants (Risk consumption)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.526</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>2.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants by Their Sociodemographic Characteristics: MEDEA</title>
        <description>Socio-demographics were characteristics of a population. One of the socio-demographics characteristics included MEDEA. MEDEA was a deprivation index that was associated with overall mortality in urban areas. It included factors like job, education, housing conditions and single parent homes. The MEDEA index was categorized in quintiles for urban areas, with quintile 1 corresponding to the least deprived population and quintile 5, the most deprived.</description>
        <time_frame>Day 1</time_frame>
        <population>Study population included all participants with a first-recorded prescription of apixaban, VKA, dabigatran or rivaroxaban for SPAF registered in SIDIAP database during the study and diagnosed with NVAF. Here, &quot;Overall Number of Participants Analyzed (N)&quot; signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban: Naive</title>
            <description>Participants who were treated with apixaban without prior prescription of vitamin K antagonists (VKA) (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date (when the participant took the drug for the first time). The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Apixaban: Non Naive</title>
            <description>Participants who were treated with apixaban with prior prescription of VKA (warfarin or acenocoumarol), dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O3">
            <title>Acenocoumarol: Naive</title>
            <description>Participants who were treated with acenocoumarol without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O4">
            <title>Acenocoumarol: Non-Naive</title>
            <description>Participants who were treated with acenocoumarol with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O5">
            <title>Warfarin: Naive</title>
            <description>Participants who were treated with warfarin without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O6">
            <title>Warfarin: Non-Naive</title>
            <description>Participants who were treated with warfarin with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O7">
            <title>Dabigatran: Naive</title>
            <description>Participants who were treated with dabigatran without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O8">
            <title>Dabigatran: Non-Naive</title>
            <description>Participants who were treated with dabigatran with prior prescription of VKA (warfarin or acenocoumarol), apixaban or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O9">
            <title>Rivaroxaban: Naive</title>
            <description>Participants who were treated with rivaroxaban without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O10">
            <title>Rivaroxaban: Non-Naive</title>
            <description>Participants who were treated with rivaroxaban with prior prescription of VKA (warfarin or acenocoumarol), apixaban and dabigatran in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants by Their Sociodemographic Characteristics: MEDEA</title>
          <description>Socio-demographics were characteristics of a population. One of the socio-demographics characteristics included MEDEA. MEDEA was a deprivation index that was associated with overall mortality in urban areas. It included factors like job, education, housing conditions and single parent homes. The MEDEA index was categorized in quintiles for urban areas, with quintile 1 corresponding to the least deprived population and quintile 5, the most deprived.</description>
          <population>Study population included all participants with a first-recorded prescription of apixaban, VKA, dabigatran or rivaroxaban for SPAF registered in SIDIAP database during the study and diagnosed with NVAF. Here, &quot;Overall Number of Participants Analyzed (N)&quot; signifies participants who were evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4027"/>
                <count group_id="O2" value="1210"/>
                <count group_id="O3" value="25477"/>
                <count group_id="O4" value="154"/>
                <count group_id="O5" value="2163"/>
                <count group_id="O6" value="322"/>
                <count group_id="O7" value="2393"/>
                <count group_id="O8" value="789"/>
                <count group_id="O9" value="4430"/>
                <count group_id="O10" value="1389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Missing - Urban area</title>
                  <measurement_list>
                    <measurement group_id="O1" value="190"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="1754"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="120"/>
                    <measurement group_id="O6" value="28"/>
                    <measurement group_id="O7" value="110"/>
                    <measurement group_id="O8" value="57"/>
                    <measurement group_id="O9" value="230"/>
                    <measurement group_id="O10" value="145"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Quintile 1 - Urban area</title>
                  <measurement_list>
                    <measurement group_id="O1" value="716"/>
                    <measurement group_id="O2" value="224"/>
                    <measurement group_id="O3" value="4735"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="149"/>
                    <measurement group_id="O6" value="73"/>
                    <measurement group_id="O7" value="558"/>
                    <measurement group_id="O8" value="156"/>
                    <measurement group_id="O9" value="973"/>
                    <measurement group_id="O10" value="230"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Quintile 2 - Urban area</title>
                  <measurement_list>
                    <measurement group_id="O1" value="754"/>
                    <measurement group_id="O2" value="216"/>
                    <measurement group_id="O3" value="4753"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="315"/>
                    <measurement group_id="O6" value="73"/>
                    <measurement group_id="O7" value="461"/>
                    <measurement group_id="O8" value="148"/>
                    <measurement group_id="O9" value="803"/>
                    <measurement group_id="O10" value="234"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Quintile 3 - Urban area</title>
                  <measurement_list>
                    <measurement group_id="O1" value="825"/>
                    <measurement group_id="O2" value="256"/>
                    <measurement group_id="O3" value="4801"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="606"/>
                    <measurement group_id="O6" value="52"/>
                    <measurement group_id="O7" value="447"/>
                    <measurement group_id="O8" value="137"/>
                    <measurement group_id="O9" value="904"/>
                    <measurement group_id="O10" value="230"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Quintile 4 - Urban area</title>
                  <measurement_list>
                    <measurement group_id="O1" value="807"/>
                    <measurement group_id="O2" value="231"/>
                    <measurement group_id="O3" value="4744"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="635"/>
                    <measurement group_id="O6" value="55"/>
                    <measurement group_id="O7" value="429"/>
                    <measurement group_id="O8" value="152"/>
                    <measurement group_id="O9" value="837"/>
                    <measurement group_id="O10" value="300"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Quintile 5 - Urban area</title>
                  <measurement_list>
                    <measurement group_id="O1" value="735"/>
                    <measurement group_id="O2" value="193"/>
                    <measurement group_id="O3" value="4690"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="338"/>
                    <measurement group_id="O6" value="41"/>
                    <measurement group_id="O7" value="388"/>
                    <measurement group_id="O8" value="139"/>
                    <measurement group_id="O9" value="683"/>
                    <measurement group_id="O10" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in naive participants (Quintile 1 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.20</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in naive participants (Quintile 2 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in naive participants (Quintile 3 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in naive participants (Quintile 4 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in naive participants (Quintile 5 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in non-naive participants (Quintile 1 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.157</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in non-naive participants (Quintile 2 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.124</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in non-naive participants (Quintile 3 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.062</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in non-naive participants (Quintile 4 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.079</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in non-naive participants (Quintile 5 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.140</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in naive participants (Quintile 1 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.17</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in naive participants (Quintile 2 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in naive participants (Quintile 3 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in naive participants (Quintile 4 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in naive participants (Quintile 5 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in non-naive participants (Quintile 1 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.157</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in non-naive participants (Quintile 2 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.124</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in non-naive participants (Quintile 3 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.062</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in non-naive participants (Quintile 4 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.079</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in non-naive participants (Quintile 5 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.140</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in naive participants (Quintile 1 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in naive participants (Quintile 2 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in naive participants (Quintile 3 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in naive participants (Quintile 4 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in naive participants (Quintile 5 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in non-naive participants (Quintile 1 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.157</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in non-naive participants (Quintile 2 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.124</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in non-naive participants (Quintile 3 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.062</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in non-naive participants (Quintile 4 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.079</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in non-naive participants (Quintile 5 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.140</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in naive participants (Quintile 1 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in naive participants (Quintile 2 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in naive participants (Quintile 3 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.51</ci_lower_limit>
            <ci_upper_limit>1.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in naive participants (Quintile 4 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.65</ci_lower_limit>
            <ci_upper_limit>2.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in naive participants (Quintile 5 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in non-naive participants (Quintile 1 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.157</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in non-naive participants (Quintile 2 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.124</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>1.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in non-naive participants (Quintile 3 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.062</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in non-naive participants (Quintile 4 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.079</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in non-naive participants (Quintile 5 - Urban area)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.140</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants by Their Sociodemographic Characteristics: Body Mass Index (BMI)</title>
        <description>Socio-demographics were characteristics of a population. One of the socio-demographics characteristics included BMI. BMI was defined as an index for assessing overweight and underweight and was obtained by dividing body weight in kilograms (kg) by height in meters squared (m^2).</description>
        <time_frame>Day 1</time_frame>
        <population>Study population included all participants with a first-recorded prescription of apixaban, VKA, dabigatran or rivaroxaban for SPAF registered in SIDIAP database during the study and diagnosed with NVAF.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban: Naive</title>
            <description>Participants who were treated with apixaban without prior prescription of vitamin K antagonists (VKA) (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date (when the participant took the drug for the first time). The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Apixaban: Non Naive</title>
            <description>Participants who were treated with apixaban with prior prescription of VKA (warfarin or acenocoumarol), dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O3">
            <title>Acenocoumarol: Naive</title>
            <description>Participants who were treated with acenocoumarol without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O4">
            <title>Acenocoumarol: Non-Naive</title>
            <description>Participants who were treated with acenocoumarol with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O5">
            <title>Warfarin: Naive</title>
            <description>Participants who were treated with warfarin without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O6">
            <title>Warfarin: Non-Naive</title>
            <description>Participants who were treated with warfarin with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O7">
            <title>Dabigatran: Naive</title>
            <description>Participants who were treated with dabigatran without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O8">
            <title>Dabigatran: Non-Naive</title>
            <description>Participants who were treated with dabigatran with prior prescription of VKA (warfarin or acenocoumarol), apixaban or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O9">
            <title>Rivaroxaban: Naive</title>
            <description>Participants who were treated with rivaroxaban without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O10">
            <title>Rivaroxaban: Non-Naive</title>
            <description>Participants who were treated with rivaroxaban with prior prescription of VKA (warfarin or acenocoumarol), apixaban and dabigatran in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants by Their Sociodemographic Characteristics: Body Mass Index (BMI)</title>
          <description>Socio-demographics were characteristics of a population. One of the socio-demographics characteristics included BMI. BMI was defined as an index for assessing overweight and underweight and was obtained by dividing body weight in kilograms (kg) by height in meters squared (m^2).</description>
          <population>Study population included all participants with a first-recorded prescription of apixaban, VKA, dabigatran or rivaroxaban for SPAF registered in SIDIAP database during the study and diagnosed with NVAF.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4712"/>
                <count group_id="O2" value="1423"/>
                <count group_id="O3" value="32212"/>
                <count group_id="O4" value="192"/>
                <count group_id="O5" value="2286"/>
                <count group_id="O6" value="363"/>
                <count group_id="O7" value="2855"/>
                <count group_id="O8" value="953"/>
                <count group_id="O9" value="5132"/>
                <count group_id="O10" value="1562"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1424"/>
                    <measurement group_id="O2" value="261"/>
                    <measurement group_id="O3" value="6898"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="509"/>
                    <measurement group_id="O6" value="87"/>
                    <measurement group_id="O7" value="960"/>
                    <measurement group_id="O8" value="178"/>
                    <measurement group_id="O9" value="1746"/>
                    <measurement group_id="O10" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18.5 - 25 kg per m^2 (Normal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="423"/>
                    <measurement group_id="O2" value="253"/>
                    <measurement group_id="O3" value="4471"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="295"/>
                    <measurement group_id="O6" value="78"/>
                    <measurement group_id="O7" value="272"/>
                    <measurement group_id="O8" value="144"/>
                    <measurement group_id="O9" value="464"/>
                    <measurement group_id="O10" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Less than (&lt;) 18.5 kg per m^2 (Underweight)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="141"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="16"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 - 30 kg per m^2 (Overweight)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1229"/>
                    <measurement group_id="O2" value="493"/>
                    <measurement group_id="O3" value="10074"/>
                    <measurement group_id="O4" value="68"/>
                    <measurement group_id="O5" value="712"/>
                    <measurement group_id="O6" value="119"/>
                    <measurement group_id="O7" value="735"/>
                    <measurement group_id="O8" value="306"/>
                    <measurement group_id="O9" value="1289"/>
                    <measurement group_id="O10" value="482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than (&gt;) 30 kg per m^2 (Obese)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1624"/>
                    <measurement group_id="O2" value="410"/>
                    <measurement group_id="O3" value="10628"/>
                    <measurement group_id="O4" value="60"/>
                    <measurement group_id="O5" value="764"/>
                    <measurement group_id="O6" value="77"/>
                    <measurement group_id="O7" value="878"/>
                    <measurement group_id="O8" value="317"/>
                    <measurement group_id="O9" value="1617"/>
                    <measurement group_id="O10" value="498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in naive participants (18.5 - 25 kg per m^2 Normal)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in naive participants (&lt;18.5 kg per m^2 Underweight)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.202</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>3.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in naive participants (25 - 30 kg per m^2 Overweight)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in naive participants (&gt;30 kg per m^2 Obese)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in non-naive participants (18.5 - 25 kg per m^2 Normal)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.083</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in non-naive participants (&lt;18.5 kg per m^2 Underweight)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>6.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in non-naive participants (25 - 30 kg per m^2 Overweight)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.227</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in non-naive participants (&gt;30 kg per m^2 Obese)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>1.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in naive participants (18.5 - 25 kg per m^2 Normal)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in naive participants (&lt;18.5 kg per m^2 Underweight)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.202</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>2.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in naive participants (25 - 30 kg per m^2 Overweight)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in naive participants (&gt;30 kg per m^2 Obese)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in non-naive participants (18.5 - 25 kg per m^2 Normal)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.083</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in non-naive participants (&lt;18.5 kg per m^2 Underweight)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in non-naive participants (25 - 30 kg per m^2 Overweight)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.227</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in non-naive participants (&gt;30 kg per m^2 Obese)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in naive participants (18.5 - 25 kg per m^2 Normal)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.47</ci_lower_limit>
            <ci_upper_limit>1.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in naive participants (&lt;18.5 kg per m^2 Underweight)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.202</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>3.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in naive participants (25 - 30 kg per m^2 Overweight)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.20</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in naive participants (&gt;30 kg per m^2 Obese)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in non-naive participants (18.5 - 25 kg per m^2 Normal)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.083</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in non-naive participants (&lt;18.5 kg per m^2 Underweight)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>8.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in non-naive participants (25 - 30 kg per m^2 Overweight)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.227</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocoumarol vs. Apixaban in non-naive participants (&gt;30 kg per m^2 Obese)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in naive participants (18.5 - 25 kg per m^2 Normal)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.28</ci_lower_limit>
            <ci_upper_limit>1.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in naive participants (&lt;18.5 kg per m^2 Underweight)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.202</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>2.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in naive participants (25 - 30 kg per m^2 Overweight)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.15</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in naive participants (&gt;30 kg per m^2 Obese)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in non-naive participants (18.5 - 25 kg per m^2 Normal)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.083</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in non-naive participants (&lt;18.5 kg per m^2 Underweight)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>6.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in non-naive participants (25 - 30 kg per m^2 Overweight)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.227</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in non-naive participants (&gt;30 kg per m^2 Obese)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants by Comorbidity</title>
        <description>Comorbidity was defined as the presence of one or more additional diseases or disorders co-occurring with (that is, concomitant or concurrent with) a primary disease or disorder.</description>
        <time_frame>Up to 12 months after date of first prescription</time_frame>
        <population>Study population included all participants with a first-recorded prescription of apixaban, VKA, dabigatran or rivaroxaban for SPAF registered in SIDIAP database during the study and diagnosed with NVAF.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban: Naive</title>
            <description>Participants who were treated with apixaban without prior prescription of vitamin K antagonists (VKA) (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date (when the participant took the drug for the first time). The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Apixaban: Non Naive</title>
            <description>Participants who were treated with apixaban with prior prescription of VKA (warfarin or acenocoumarol), dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O3">
            <title>Acenocoumarol: Naive</title>
            <description>Participants who were treated with acenocoumarol without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O4">
            <title>Acenocoumarol: Non-Naive</title>
            <description>Participants who were treated with acenocoumarol with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O5">
            <title>Warfarin: Naive</title>
            <description>Participants who were treated with warfarin without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O6">
            <title>Warfarin: Non-Naive</title>
            <description>Participants who were treated with warfarin with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O7">
            <title>Dabigatran: Naive</title>
            <description>Participants who were treated with dabigatran without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O8">
            <title>Dabigatran: Non-Naive</title>
            <description>Participants who were treated with dabigatran with prior prescription of VKA (warfarin or acenocoumarol), apixaban or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O9">
            <title>Rivaroxaban: Naive</title>
            <description>Participants who were treated with rivaroxaban without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O10">
            <title>Rivaroxaban: Non-Naive</title>
            <description>Participants who were treated with rivaroxaban with prior prescription of VKA (warfarin or acenocoumarol), apixaban and dabigatran in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants by Comorbidity</title>
          <description>Comorbidity was defined as the presence of one or more additional diseases or disorders co-occurring with (that is, concomitant or concurrent with) a primary disease or disorder.</description>
          <population>Study population included all participants with a first-recorded prescription of apixaban, VKA, dabigatran or rivaroxaban for SPAF registered in SIDIAP database during the study and diagnosed with NVAF.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4712"/>
                <count group_id="O2" value="1423"/>
                <count group_id="O3" value="32212"/>
                <count group_id="O4" value="192"/>
                <count group_id="O5" value="2286"/>
                <count group_id="O6" value="363"/>
                <count group_id="O7" value="2855"/>
                <count group_id="O8" value="953"/>
                <count group_id="O9" value="5132"/>
                <count group_id="O10" value="1562"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3695"/>
                    <measurement group_id="O2" value="1316"/>
                    <measurement group_id="O3" value="26450"/>
                    <measurement group_id="O4" value="173"/>
                    <measurement group_id="O5" value="1819"/>
                    <measurement group_id="O6" value="318"/>
                    <measurement group_id="O7" value="2030"/>
                    <measurement group_id="O8" value="870"/>
                    <measurement group_id="O9" value="3731"/>
                    <measurement group_id="O10" value="1417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in naive participants</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in non-naive participants</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.052</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in naive participants</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in non-naive participants</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.052</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Acenocumarol vs. Apixaban in naive participants</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.17</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocumarol vs. Apixaban in non-naive participants</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.052</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in naive participants</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in non-naive participants</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.052</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Risk of Bleeding Events: HAS-BLED Score</title>
        <description>Risk of bleeding events was assessed by using HAS-BLED score. HAS-BLED was a scoring system that was developed to assess 1 year risk of occurrence of major hemorrhage. HAS-BLED score was assessed by combining score of 9 risk factors: hypertension history, renal disease, liver disease, stroke history, prior major bleeding or predisposition to bleeding, labile international normalized ratio (INR), age &gt;65 years, medication usage predisposing to bleeding and alcohol or drug usage history. The total score ranged from 0 to 9 where 0 = low risk of bleed per 100 participants-year and &gt;3 = high risk of bleed per 100 participants-year.</description>
        <time_frame>Up to 12 months prior to enrollment</time_frame>
        <population>Study population included all participants with a first-recorded prescription of apixaban, VKA, dabigatran or rivaroxaban for SPAF registered in SIDIAP database during the study and diagnosed with NVAF.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban: Naive</title>
            <description>Participants who were treated with apixaban without prior prescription of vitamin K antagonists (VKA) (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date (when the participant took the drug for the first time). The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Apixaban: Non Naive</title>
            <description>Participants who were treated with apixaban with prior prescription of VKA (warfarin or acenocoumarol), dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O3">
            <title>Acenocoumarol: Naive</title>
            <description>Participants who were treated with acenocoumarol without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O4">
            <title>Acenocoumarol: Non-Naive</title>
            <description>Participants who were treated with acenocoumarol with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O5">
            <title>Warfarin: Naive</title>
            <description>Participants who were treated with warfarin without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O6">
            <title>Warfarin: Non-Naive</title>
            <description>Participants who were treated with warfarin with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O7">
            <title>Dabigatran: Naive</title>
            <description>Participants who were treated with dabigatran without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O8">
            <title>Dabigatran: Non-Naive</title>
            <description>Participants who were treated with dabigatran with prior prescription of VKA (warfarin or acenocoumarol), apixaban or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O9">
            <title>Rivaroxaban: Naive</title>
            <description>Participants who were treated with rivaroxaban without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O10">
            <title>Rivaroxaban: Non-Naive</title>
            <description>Participants who were treated with rivaroxaban with prior prescription of VKA (warfarin or acenocoumarol), apixaban and dabigatran in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Risk of Bleeding Events: HAS-BLED Score</title>
          <description>Risk of bleeding events was assessed by using HAS-BLED score. HAS-BLED was a scoring system that was developed to assess 1 year risk of occurrence of major hemorrhage. HAS-BLED score was assessed by combining score of 9 risk factors: hypertension history, renal disease, liver disease, stroke history, prior major bleeding or predisposition to bleeding, labile international normalized ratio (INR), age &gt;65 years, medication usage predisposing to bleeding and alcohol or drug usage history. The total score ranged from 0 to 9 where 0 = low risk of bleed per 100 participants-year and &gt;3 = high risk of bleed per 100 participants-year.</description>
          <population>Study population included all participants with a first-recorded prescription of apixaban, VKA, dabigatran or rivaroxaban for SPAF registered in SIDIAP database during the study and diagnosed with NVAF.</population>
          <units>bleed per 100 participants-year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4712"/>
                <count group_id="O2" value="1423"/>
                <count group_id="O3" value="32212"/>
                <count group_id="O4" value="192"/>
                <count group_id="O5" value="2286"/>
                <count group_id="O6" value="363"/>
                <count group_id="O7" value="2855"/>
                <count group_id="O8" value="953"/>
                <count group_id="O9" value="5132"/>
                <count group_id="O10" value="1562"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.0"/>
                    <measurement group_id="O2" value="2.7" spread="1.1"/>
                    <measurement group_id="O3" value="2.2" spread="1.1"/>
                    <measurement group_id="O4" value="2.5" spread="1.0"/>
                    <measurement group_id="O5" value="1.9" spread="1.1"/>
                    <measurement group_id="O6" value="2.4" spread="1.2"/>
                    <measurement group_id="O7" value="1.5" spread="1.0"/>
                    <measurement group_id="O8" value="2.6" spread="1.0"/>
                    <measurement group_id="O9" value="1.6" spread="1.0"/>
                    <measurement group_id="O10" value="2.6" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in naive participants (HAS - BLED)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.26</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in non-naive participants (HAS - BLED)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in naive participants (HAS - BLED)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.23</ci_lower_limit>
            <ci_upper_limit>-0.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in non-naive participants (HAS - BLED)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>-0.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Acenocumarol vs. Apixaban in naive participants (HAS - BLED)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocumarol vs. Apixaban in non-naive participants (HAS - BLED)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.32</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in naive participants (HAS - BLED)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.12</ci_lower_limit>
            <ci_upper_limit>0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in non-naive participants (HAS - BLED)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>-0.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Risk of Thromboembolic Events: CHADS2 Score</title>
        <description>Thromboembolic events were defined as an embolic stroke that occurred when a blood clot that formed elsewhere in the body breaks loose and travels to the brain via bloodstream. Risk of thromboembolic events was calculated using CHADS2 score. CHADS2 score was assessed by combining score of 5 risk factors (congestive heart failure history, hypertension history, age &gt;=75 years, diabetes mellitus history and stroke/transient ischemic attack symptoms previously). Total CHADS2 score ranged from 0-6 where 0 =low risk and 6 =high risk of stroke.</description>
        <time_frame>Up to 12 months prior to enrollment</time_frame>
        <population>Study population included all participants with a first-recorded prescription of apixaban, VKA, dabigatran or rivaroxaban for SPAF registered in SIDIAP database during the study and diagnosed with NVAF.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban: Naive</title>
            <description>Participants who were treated with apixaban without prior prescription of vitamin K antagonists (VKA) (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date (when the participant took the drug for the first time). The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Apixaban: Non Naive</title>
            <description>Participants who were treated with apixaban with prior prescription of VKA (warfarin or acenocoumarol), dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O3">
            <title>Acenocoumarol: Naive</title>
            <description>Participants who were treated with acenocoumarol without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O4">
            <title>Acenocoumarol: Non-Naive</title>
            <description>Participants who were treated with acenocoumarol with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O5">
            <title>Warfarin: Naive</title>
            <description>Participants who were treated with warfarin without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O6">
            <title>Warfarin: Non-Naive</title>
            <description>Participants who were treated with warfarin with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O7">
            <title>Dabigatran: Naive</title>
            <description>Participants who were treated with dabigatran without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O8">
            <title>Dabigatran: Non-Naive</title>
            <description>Participants who were treated with dabigatran with prior prescription of VKA (warfarin or acenocoumarol), apixaban or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O9">
            <title>Rivaroxaban: Naive</title>
            <description>Participants who were treated with rivaroxaban without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O10">
            <title>Rivaroxaban: Non-Naive</title>
            <description>Participants who were treated with rivaroxaban with prior prescription of VKA (warfarin or acenocoumarol), apixaban and dabigatran in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Risk of Thromboembolic Events: CHADS2 Score</title>
          <description>Thromboembolic events were defined as an embolic stroke that occurred when a blood clot that formed elsewhere in the body breaks loose and travels to the brain via bloodstream. Risk of thromboembolic events was calculated using CHADS2 score. CHADS2 score was assessed by combining score of 5 risk factors (congestive heart failure history, hypertension history, age &gt;=75 years, diabetes mellitus history and stroke/transient ischemic attack symptoms previously). Total CHADS2 score ranged from 0-6 where 0 =low risk and 6 =high risk of stroke.</description>
          <population>Study population included all participants with a first-recorded prescription of apixaban, VKA, dabigatran or rivaroxaban for SPAF registered in SIDIAP database during the study and diagnosed with NVAF.</population>
          <units>stroke risk per year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4712"/>
                <count group_id="O2" value="1423"/>
                <count group_id="O3" value="32212"/>
                <count group_id="O4" value="192"/>
                <count group_id="O5" value="2286"/>
                <count group_id="O6" value="363"/>
                <count group_id="O7" value="2855"/>
                <count group_id="O8" value="953"/>
                <count group_id="O9" value="5132"/>
                <count group_id="O10" value="1562"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.3"/>
                    <measurement group_id="O2" value="2.8" spread="1.4"/>
                    <measurement group_id="O3" value="1.9" spread="1.3"/>
                    <measurement group_id="O4" value="2.3" spread="1.3"/>
                    <measurement group_id="O5" value="1.8" spread="1.3"/>
                    <measurement group_id="O6" value="2.5" spread="1.5"/>
                    <measurement group_id="O7" value="1.5" spread="1.3"/>
                    <measurement group_id="O8" value="2.6" spread="1.4"/>
                    <measurement group_id="O9" value="1.5" spread="1.2"/>
                    <measurement group_id="O10" value="2.6" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in naive participants (CHADS2)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in non-naive participants (CHADS2)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in naive participants (CHADS2)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in non-naive participants (CHADS2)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Acenocumarol vs. Apixaban in naive participants (CHADS2)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocumarol vs. Apixaban in non-naive participants (CHADS2)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.70</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in naive participants (CHADS2)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in non-naive participants (CHADS2)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.54</ci_lower_limit>
            <ci_upper_limit>-0.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Risk of Thromboembolic Events: CHA2DS2Vasc Score</title>
        <description>Thromboembolic events were defined as an embolic stroke that occurred when a blood clot that formed elsewhere in the body breaks loose and travels to the brain via bloodstream. Risk of thromboembolic events was calculated using CHA2DS2Vasc score. CHA2DS2Vasc score was assessed by combining score of 8 risk factors (female, &gt;=65 and &lt;75 years, congestive heart failure history, hypertension history, diabetes mellitus history, vascular disease history, age &gt;=75 years and stroke/TIA symptoms previously). Total CHA2DS2Vasc score ranged from 0-9 where 0=low risk and 9=high risk of stroke.</description>
        <time_frame>Up to 12 months prior to enrollment</time_frame>
        <population>Study population included all participants with a first-recorded prescription of apixaban, VKA, dabigatran or rivaroxaban for SPAF registered in SIDIAP database during the study and diagnosed with NVAF.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban: Naive</title>
            <description>Participants who were treated with apixaban without prior prescription of vitamin K antagonists (VKA) (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date (when the participant took the drug for the first time). The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Apixaban: Non Naive</title>
            <description>Participants who were treated with apixaban with prior prescription of VKA (warfarin or acenocoumarol), dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O3">
            <title>Acenocoumarol: Naive</title>
            <description>Participants who were treated with acenocoumarol without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O4">
            <title>Acenocoumarol: Non-Naive</title>
            <description>Participants who were treated with acenocoumarol with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O5">
            <title>Warfarin: Naive</title>
            <description>Participants who were treated with warfarin without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O6">
            <title>Warfarin: Non-Naive</title>
            <description>Participants who were treated with warfarin with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O7">
            <title>Dabigatran: Naive</title>
            <description>Participants who were treated with dabigatran without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O8">
            <title>Dabigatran: Non-Naive</title>
            <description>Participants who were treated with dabigatran with prior prescription of VKA (warfarin or acenocoumarol), apixaban or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O9">
            <title>Rivaroxaban: Naive</title>
            <description>Participants who were treated with rivaroxaban without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O10">
            <title>Rivaroxaban: Non-Naive</title>
            <description>Participants who were treated with rivaroxaban with prior prescription of VKA (warfarin or acenocoumarol), apixaban and dabigatran in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Risk of Thromboembolic Events: CHA2DS2Vasc Score</title>
          <description>Thromboembolic events were defined as an embolic stroke that occurred when a blood clot that formed elsewhere in the body breaks loose and travels to the brain via bloodstream. Risk of thromboembolic events was calculated using CHA2DS2Vasc score. CHA2DS2Vasc score was assessed by combining score of 8 risk factors (female, &gt;=65 and &lt;75 years, congestive heart failure history, hypertension history, diabetes mellitus history, vascular disease history, age &gt;=75 years and stroke/TIA symptoms previously). Total CHA2DS2Vasc score ranged from 0-9 where 0=low risk and 9=high risk of stroke.</description>
          <population>Study population included all participants with a first-recorded prescription of apixaban, VKA, dabigatran or rivaroxaban for SPAF registered in SIDIAP database during the study and diagnosed with NVAF.</population>
          <units>stroke risk per year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4712"/>
                <count group_id="O2" value="1423"/>
                <count group_id="O3" value="32212"/>
                <count group_id="O4" value="192"/>
                <count group_id="O5" value="2286"/>
                <count group_id="O6" value="363"/>
                <count group_id="O7" value="2855"/>
                <count group_id="O8" value="953"/>
                <count group_id="O9" value="5132"/>
                <count group_id="O10" value="1562"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="1.7"/>
                    <measurement group_id="O2" value="4.4" spread="1.6"/>
                    <measurement group_id="O3" value="3.2" spread="1.7"/>
                    <measurement group_id="O4" value="3.7" spread="1.6"/>
                    <measurement group_id="O5" value="2.9" spread="1.8"/>
                    <measurement group_id="O6" value="3.9" spread="1.9"/>
                    <measurement group_id="O7" value="2.7" spread="1.8"/>
                    <measurement group_id="O8" value="4.0" spread="1.7"/>
                    <measurement group_id="O9" value="2.7" spread="1.7"/>
                    <measurement group_id="O10" value="4.1" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in naive participants (CHA2DS2Vasc)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.42</ci_lower_limit>
            <ci_upper_limit>-0.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in non-naive participants (CHA2DS2Vasc)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>-0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in naive participants (CHA2DS2Vasc)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>-0.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in non-naive participants (CHA2DS2Vasc)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.39</ci_lower_limit>
            <ci_upper_limit>-0.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Acenocumarol vs. Apixaban in naive participants (CHA2DS2Vasc)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>0.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocumarol vs. Apixaban in non-naive participants (CHA2DS2Vasc)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.86</ci_lower_limit>
            <ci_upper_limit>-0.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in naive participants (CHA2DS2Vasc)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in non-naive participants (CHA2DS2Vasc)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.64</ci_lower_limit>
            <ci_upper_limit>-0.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants by Comedications</title>
        <description>Comedication was defined as the second or alternative medication used to relieve the side-effects of another medicine.</description>
        <time_frame>Up to 30 days after date of first prescription</time_frame>
        <population>Study population included all participants with a first-recorded prescription of apixaban, VKA, dabigatran or rivaroxaban for SPAF registered in SIDIAP database during the study and diagnosed with NVAF.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban: Naive</title>
            <description>Participants who were treated with apixaban without prior prescription of vitamin K antagonists (VKA) (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date (when the participant took the drug for the first time). The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Apixaban: Non Naive</title>
            <description>Participants who were treated with apixaban with prior prescription of VKA (warfarin or acenocoumarol), dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O3">
            <title>Acenocoumarol: Naive</title>
            <description>Participants who were treated with acenocoumarol without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O4">
            <title>Acenocoumarol: Non-Naive</title>
            <description>Participants who were treated with acenocoumarol with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O5">
            <title>Warfarin: Naive</title>
            <description>Participants who were treated with warfarin without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O6">
            <title>Warfarin: Non-Naive</title>
            <description>Participants who were treated with warfarin with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O7">
            <title>Dabigatran: Naive</title>
            <description>Participants who were treated with dabigatran without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O8">
            <title>Dabigatran: Non-Naive</title>
            <description>Participants who were treated with dabigatran with prior prescription of VKA (warfarin or acenocoumarol), apixaban or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O9">
            <title>Rivaroxaban: Naive</title>
            <description>Participants who were treated with rivaroxaban without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O10">
            <title>Rivaroxaban: Non-Naive</title>
            <description>Participants who were treated with rivaroxaban with prior prescription of VKA (warfarin or acenocoumarol), apixaban and dabigatran in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants by Comedications</title>
          <description>Comedication was defined as the second or alternative medication used to relieve the side-effects of another medicine.</description>
          <population>Study population included all participants with a first-recorded prescription of apixaban, VKA, dabigatran or rivaroxaban for SPAF registered in SIDIAP database during the study and diagnosed with NVAF.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4712"/>
                <count group_id="O2" value="1423"/>
                <count group_id="O3" value="32212"/>
                <count group_id="O4" value="192"/>
                <count group_id="O5" value="2286"/>
                <count group_id="O6" value="363"/>
                <count group_id="O7" value="2855"/>
                <count group_id="O8" value="953"/>
                <count group_id="O9" value="5132"/>
                <count group_id="O10" value="1562"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4712"/>
                    <measurement group_id="O2" value="1406"/>
                    <measurement group_id="O3" value="32212"/>
                    <measurement group_id="O4" value="188"/>
                    <measurement group_id="O5" value="2286"/>
                    <measurement group_id="O6" value="352"/>
                    <measurement group_id="O7" value="2855"/>
                    <measurement group_id="O8" value="947"/>
                    <measurement group_id="O9" value="5132"/>
                    <measurement group_id="O10" value="1532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in non-naive participants</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>5.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in non-naive participants</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocumarol vs. Apixaban in non-naive participants</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.20</ci_lower_limit>
            <ci_upper_limit>1.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in non-naive participants</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Apixaban Adherence With VKA, Dabigatran and Rivaroxaban as Assessed by Medication Possession Ratio (MPR)</title>
        <description>MPR was one of the methods of measuring adherence and was defined as the ratio of all days supply to elapsed days, during the 12-month observation period. All days supply defined as sum of number of days supply between the start date and last prescription dispensed. Elapsed days defined as number of days between the start date and the last prescription dispensed. There were three categories of adherence: poor defined as &lt;80% of MPR, good defined as between 80% and 120% of MPR and over adherence defined as &gt;120% of MPR.</description>
        <time_frame>Up to 12 months after date of first prescription</time_frame>
        <population>Study population included all participants with a first-recorded prescription of apixaban, VKA, dabigatran or rivaroxaban for SPAF registered in SIDIAP database during the study and diagnosed with NVAF. Here &quot;N&quot; signifies number of participants evaluable for the specified outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban: Naive</title>
            <description>Participants who were treated with apixaban without prior prescription of vitamin K antagonists (VKA) (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date (when the participant took the drug for the first time). The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Apixaban: Non Naive</title>
            <description>Participants who were treated with apixaban with prior prescription of VKA (warfarin or acenocoumarol), dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O3">
            <title>Acenocoumarol: Naive</title>
            <description>Participants who were treated with acenocoumarol without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O4">
            <title>Acenocoumarol: Non-Naive</title>
            <description>Participants who were treated with acenocoumarol with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O5">
            <title>Warfarin: Naive</title>
            <description>Participants who were treated with warfarin without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O6">
            <title>Warfarin: Non-Naive</title>
            <description>Participants who were treated with warfarin with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O7">
            <title>Dabigatran: Naive</title>
            <description>Participants who were treated with dabigatran without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O8">
            <title>Dabigatran: Non-Naive</title>
            <description>Participants who were treated with dabigatran with prior prescription of VKA (warfarin or acenocoumarol), apixaban or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O9">
            <title>Rivaroxaban: Naive</title>
            <description>Participants who were treated with rivaroxaban without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O10">
            <title>Rivaroxaban: Non-Naive</title>
            <description>Participants who were treated with rivaroxaban with prior prescription of VKA (warfarin or acenocoumarol), apixaban and dabigatran in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Apixaban Adherence With VKA, Dabigatran and Rivaroxaban as Assessed by Medication Possession Ratio (MPR)</title>
          <description>MPR was one of the methods of measuring adherence and was defined as the ratio of all days supply to elapsed days, during the 12-month observation period. All days supply defined as sum of number of days supply between the start date and last prescription dispensed. Elapsed days defined as number of days between the start date and the last prescription dispensed. There were three categories of adherence: poor defined as &lt;80% of MPR, good defined as between 80% and 120% of MPR and over adherence defined as &gt;120% of MPR.</description>
          <population>Study population included all participants with a first-recorded prescription of apixaban, VKA, dabigatran or rivaroxaban for SPAF registered in SIDIAP database during the study and diagnosed with NVAF. Here &quot;N&quot; signifies number of participants evaluable for the specified outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="430"/>
                <count group_id="O3" value="6108"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="344"/>
                <count group_id="O6" value="79"/>
                <count group_id="O7" value="447"/>
                <count group_id="O8" value="311"/>
                <count group_id="O9" value="527"/>
                <count group_id="O10" value="495"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>MPR: Poor adherence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                    <measurement group_id="O2" value="151"/>
                    <measurement group_id="O3" value="5634"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="103"/>
                    <measurement group_id="O6" value="57"/>
                    <measurement group_id="O7" value="241"/>
                    <measurement group_id="O8" value="177"/>
                    <measurement group_id="O9" value="147"/>
                    <measurement group_id="O10" value="131"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MPR: Good adherence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="259"/>
                    <measurement group_id="O2" value="276"/>
                    <measurement group_id="O3" value="460"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="151"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="206"/>
                    <measurement group_id="O8" value="133"/>
                    <measurement group_id="O9" value="378"/>
                    <measurement group_id="O10" value="360"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MPR: Over adherence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="90"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in naive participants (Poor adherence)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.14</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in naive participants (Good adherence)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in naive participants (Over adherence)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.03</ci_lower_limit>
            <ci_upper_limit>2.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in non-naive participants (Poor adherence)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.23</ci_lower_limit>
            <ci_upper_limit>2.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in non-naive participants (Good adherence)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in non-naive participants (Over adherence)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>3.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in naive participants (Poor adherence)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in naive participants (Good adherence)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in naive participants (Over adherence)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>3.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in non-naive participants (Poor adherence)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in non-naive participants (Good adherence)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in non-naive participants (Over adherence)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.22</ci_lower_limit>
            <ci_upper_limit>5.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Acenocumarol vs. Apixaban in naive participants (Poor adherence)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.86</ci_lower_limit>
            <ci_upper_limit>3.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Acenocumarol vs. Apixaban in naive participants (Good adherence)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Acenocumarol vs. Apixaban in naive participants (Over adherence)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.11</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocumarol vs. Apixaban in non-naive participants (Poor adherence)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocumarol vs. Apixaban in non-naive participants (Good adherence)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.00</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocumarol vs. Apixaban in non-naive participants (Over adherence)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.07</ci_lower_limit>
            <ci_upper_limit>18.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in naive participants (Poor adherence)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in naive participants (Good adherence)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in naive participants (Over adherence)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>29.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.01</ci_lower_limit>
            <ci_upper_limit>123.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in non-naive participants (Poor adherence)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in non-naive participants (Good adherence)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in non-naive participants (Over adherence)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>9.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.81</ci_lower_limit>
            <ci_upper_limit>46.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Apixaban Adherence With VKA, Dabigatran and Rivaroxaban as Assessed by Discontinuation Throughout the Year</title>
        <description>Discontinuation rate was defined as the lack of subsequent prescription of the index drugs within 2 months after last supply day of the last prescription. It was analyzed by calculating the treatment withdrawal or switch rate.</description>
        <time_frame>Up to 12 months after date of first prescription</time_frame>
        <population>Study population included all participants with a first-recorded prescription of apixaban, VKA, dabigatran or rivaroxaban for SPAF registered in SIDIAP database during the study and diagnosed with NVAF. Here &quot;N&quot; signifies number of participants evaluable for the specified outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban: Naive</title>
            <description>Participants who were treated with apixaban without prior prescription of vitamin K antagonists (VKA) (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date (when the participant took the drug for the first time). The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Apixaban: Non Naive</title>
            <description>Participants who were treated with apixaban with prior prescription of VKA (warfarin or acenocoumarol), dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O3">
            <title>Acenocoumarol: Naive</title>
            <description>Participants who were treated with acenocoumarol without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O4">
            <title>Acenocoumarol: Non-Naive</title>
            <description>Participants who were treated with acenocoumarol with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O5">
            <title>Warfarin: Naive</title>
            <description>Participants who were treated with warfarin without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O6">
            <title>Warfarin: Non-Naive</title>
            <description>Participants who were treated with warfarin with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O7">
            <title>Dabigatran: Naive</title>
            <description>Participants who were treated with dabigatran without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O8">
            <title>Dabigatran: Non-Naive</title>
            <description>Participants who were treated with dabigatran with prior prescription of VKA (warfarin or acenocoumarol), apixaban or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O9">
            <title>Rivaroxaban: Naive</title>
            <description>Participants who were treated with rivaroxaban without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O10">
            <title>Rivaroxaban: Non-Naive</title>
            <description>Participants who were treated with rivaroxaban with prior prescription of VKA (warfarin or acenocoumarol), apixaban and dabigatran in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Apixaban Adherence With VKA, Dabigatran and Rivaroxaban as Assessed by Discontinuation Throughout the Year</title>
          <description>Discontinuation rate was defined as the lack of subsequent prescription of the index drugs within 2 months after last supply day of the last prescription. It was analyzed by calculating the treatment withdrawal or switch rate.</description>
          <population>Study population included all participants with a first-recorded prescription of apixaban, VKA, dabigatran or rivaroxaban for SPAF registered in SIDIAP database during the study and diagnosed with NVAF. Here &quot;N&quot; signifies number of participants evaluable for the specified outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1305"/>
                <count group_id="O2" value="666"/>
                <count group_id="O3" value="17434"/>
                <count group_id="O4" value="117"/>
                <count group_id="O5" value="1353"/>
                <count group_id="O6" value="206"/>
                <count group_id="O7" value="1449"/>
                <count group_id="O8" value="559"/>
                <count group_id="O9" value="1718"/>
                <count group_id="O10" value="817"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="881"/>
                    <measurement group_id="O2" value="236"/>
                    <measurement group_id="O3" value="11326"/>
                    <measurement group_id="O4" value="85"/>
                    <measurement group_id="O5" value="1009"/>
                    <measurement group_id="O6" value="127"/>
                    <measurement group_id="O7" value="1002"/>
                    <measurement group_id="O8" value="248"/>
                    <measurement group_id="O9" value="1191"/>
                    <measurement group_id="O10" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in naive participants (Discontinuation first year)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in non-naive participants (Discontinuation first year)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.15</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in naive participants (Discontinuation first year)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in non-naive participants (Discontinuation first year)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Acenocumarol vs. Apixaban in naive participants (Discontinuation first year)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocumarol vs. Apixaban in non-naive participants (Discontinuation first year)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.14</ci_lower_limit>
            <ci_upper_limit>7.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in naive participants (Discontinuation first year)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.19</ci_lower_limit>
            <ci_upper_limit>1.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in non-naive participants (Discontinuation first year)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>Chi-squared</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.12</ci_lower_limit>
            <ci_upper_limit>4.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apixaban Adherence With VKA, Dabigatran and Rivaroxaban by Number of Defined Daily Dose (NDDD)</title>
        <description>NDDD was a measure that represented the average daily maintenance dose for the main indication of a drug.</description>
        <time_frame>Up to 12 months after date of first prescription</time_frame>
        <population>Study population included all participants with a first-recorded prescription of apixaban, VKA, dabigatran or rivaroxaban for SPAF registered in SIDIAP database during the study and diagnosed with NVAF. Here &quot;N&quot; signifies number of participants evaluable for the specified outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban: Naive</title>
            <description>Participants who were treated with apixaban without prior prescription of vitamin K antagonists (VKA) (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date (when the participant took the drug for the first time). The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Apixaban: Non Naive</title>
            <description>Participants who were treated with apixaban with prior prescription of VKA (warfarin or acenocoumarol), dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O3">
            <title>Acenocoumarol: Naive</title>
            <description>Participants who were treated with acenocoumarol without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O4">
            <title>Acenocoumarol: Non-Naive</title>
            <description>Participants who were treated with acenocoumarol with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O5">
            <title>Warfarin: Naive</title>
            <description>Participants who were treated with warfarin without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O6">
            <title>Warfarin: Non-Naive</title>
            <description>Participants who were treated with warfarin with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O7">
            <title>Dabigatran: Naive</title>
            <description>Participants who were treated with dabigatran without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O8">
            <title>Dabigatran: Non-Naive</title>
            <description>Participants who were treated with dabigatran with prior prescription of VKA (warfarin or acenocoumarol), apixaban or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O9">
            <title>Rivaroxaban: Naive</title>
            <description>Participants who were treated with rivaroxaban without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O10">
            <title>Rivaroxaban: Non-Naive</title>
            <description>Participants who were treated with rivaroxaban with prior prescription of VKA (warfarin or acenocoumarol), apixaban and dabigatran in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Apixaban Adherence With VKA, Dabigatran and Rivaroxaban by Number of Defined Daily Dose (NDDD)</title>
          <description>NDDD was a measure that represented the average daily maintenance dose for the main indication of a drug.</description>
          <population>Study population included all participants with a first-recorded prescription of apixaban, VKA, dabigatran or rivaroxaban for SPAF registered in SIDIAP database during the study and diagnosed with NVAF. Here &quot;N&quot; signifies number of participants evaluable for the specified outcome measure.</population>
          <units>milligrams per day</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1305"/>
                <count group_id="O2" value="666"/>
                <count group_id="O3" value="17434"/>
                <count group_id="O4" value="117"/>
                <count group_id="O5" value="1353"/>
                <count group_id="O6" value="206"/>
                <count group_id="O7" value="1449"/>
                <count group_id="O8" value="559"/>
                <count group_id="O9" value="1718"/>
                <count group_id="O10" value="817"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="15.0" upper_limit="30.0"/>
                    <measurement group_id="O2" value="30.0" lower_limit="15.0" upper_limit="30.0"/>
                    <measurement group_id="O3" value="16.0" lower_limit="16.0" upper_limit="32.0"/>
                    <measurement group_id="O4" value="16.0" lower_limit="16.0" upper_limit="32.0"/>
                    <measurement group_id="O5" value="53.0" lower_limit="53.0" upper_limit="53.0"/>
                    <measurement group_id="O6" value="16.0" lower_limit="5.0" upper_limit="53.0"/>
                    <measurement group_id="O7" value="22.0" lower_limit="22.0" upper_limit="29.0"/>
                    <measurement group_id="O8" value="22.0" lower_limit="22.0" upper_limit="29.0"/>
                    <measurement group_id="O9" value="21.0" lower_limit="15.0" upper_limit="28.0"/>
                    <measurement group_id="O10" value="28.0" lower_limit="21.0" upper_limit="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in naive participants (NDDDs)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.02</ci_lower_limit>
            <ci_upper_limit>4.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Dabigatran vs. Apixaban in non-naive participants (NDDDs)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.77</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in naive participants (NDDDs)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>2.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Rivaroxaban vs. Apixaban in non-naive participants (NDDDs)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.16</ci_lower_limit>
            <ci_upper_limit>2.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Acenocumarol vs. Apixaban in naive participants (NDDDs)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Acenocumarol vs. Apixaban in non-naive participants (NDDDs)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.32</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in naive participants (NDDDs)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>28.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>27.56</ci_lower_limit>
            <ci_upper_limit>29.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Warfarin vs. Apixaban in non-naive participants (NDDDs)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.05</ci_lower_limit>
            <ci_upper_limit>4.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>International Normalized Ratio (INR) Values During the Last 12 Months Values in Participants Previously Treated With VKA</title>
        <description>INR was defined as the ratio of the participant's prothrombin time and the normal mean prothrombin time. Prothrombin time defined as a time taken by the blood to clot in participants receiving oral anticoagulant medication. INR was categorized according to the risk level: risk for coagulation (INR&lt;2); optimal range (2&lt;INR&lt;3); and risk of hemorrhages (INR&gt;3).</description>
        <time_frame>Up to 12 months after date of first prescription</time_frame>
        <population>Study population included all participants with a first-recorded prescription of VKA for SPAF registered in SIDIAP database during the study and diagnosed with NVAF. Here &quot;N&quot; signifies number of participants evaluable for the specified outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Acenocoumarol: Naive</title>
            <description>Participants who were treated with acenocoumarol without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Acenocoumarol: Non-Naive</title>
            <description>Participants who were treated with acenocoumarol with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O3">
            <title>Warfarin: Naive</title>
            <description>Participants who were treated with warfarin without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O4">
            <title>Warfarin: Non-Naive</title>
            <description>Participants who were treated with warfarin with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
        </group_list>
        <measure>
          <title>International Normalized Ratio (INR) Values During the Last 12 Months Values in Participants Previously Treated With VKA</title>
          <description>INR was defined as the ratio of the participant's prothrombin time and the normal mean prothrombin time. Prothrombin time defined as a time taken by the blood to clot in participants receiving oral anticoagulant medication. INR was categorized according to the risk level: risk for coagulation (INR&lt;2); optimal range (2&lt;INR&lt;3); and risk of hemorrhages (INR&gt;3).</description>
          <population>Study population included all participants with a first-recorded prescription of VKA for SPAF registered in SIDIAP database during the study and diagnosed with NVAF. Here &quot;N&quot; signifies number of participants evaluable for the specified outcome measure.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19192"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="872"/>
                <count group_id="O4" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.4"/>
                    <measurement group_id="O2" value="2.5" spread="0.4"/>
                    <measurement group_id="O3" value="2.5" spread="0.3"/>
                    <measurement group_id="O4" value="2.6" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time in Therapeutic Range (TTR) Values During the Last 12 Months Values in Participants Previously Treated With VKA</title>
        <description>TTR was defined as the duration of time in which the participant's INR values were within a desired range (2 to 3). INR was defined as the ratio of the participant's prothrombin time and the normal mean prothrombin time. Prothrombin time defined as a time taken by the blood to clot in participants receiving oral anticoagulant medication. INR was categorized according to the risk level: risk for coagulation (INR&lt;2); optimal range (2&lt;INR&lt;3); and risk of hemorrhages (INR&gt;3).</description>
        <time_frame>Up to 12 months after date of first prescription</time_frame>
        <population>Study population included all participants with a first-recorded prescription of VKA for SPAF registered in SIDIAP database during the study and diagnosed with NVAF. Here &quot;N&quot; signifies number of participants evaluable for the specified outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Acenocoumarol: Naive</title>
            <description>Participants who were treated with acenocoumarol without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O2">
            <title>Acenocoumarol: Non-Naive</title>
            <description>Participants who were treated with acenocoumarol with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O3">
            <title>Warfarin: Naive</title>
            <description>Participants who were treated with warfarin without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
          <group group_id="O4">
            <title>Warfarin: Non-Naive</title>
            <description>Participants who were treated with warfarin with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
          </group>
        </group_list>
        <measure>
          <title>Time in Therapeutic Range (TTR) Values During the Last 12 Months Values in Participants Previously Treated With VKA</title>
          <description>TTR was defined as the duration of time in which the participant's INR values were within a desired range (2 to 3). INR was defined as the ratio of the participant's prothrombin time and the normal mean prothrombin time. Prothrombin time defined as a time taken by the blood to clot in participants receiving oral anticoagulant medication. INR was categorized according to the risk level: risk for coagulation (INR&lt;2); optimal range (2&lt;INR&lt;3); and risk of hemorrhages (INR&gt;3).</description>
          <population>Study population included all participants with a first-recorded prescription of VKA for SPAF registered in SIDIAP database during the study and diagnosed with NVAF. Here &quot;N&quot; signifies number of participants evaluable for the specified outcome measure.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19192"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="872"/>
                <count group_id="O4" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.2" lower_limit="47.2" upper_limit="71.8"/>
                    <measurement group_id="O2" value="59.6" lower_limit="47.7" upper_limit="68.4"/>
                    <measurement group_id="O3" value="66.2" lower_limit="52.2" upper_limit="77.4"/>
                    <measurement group_id="O4" value="58.9" lower_limit="43.2" upper_limit="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Not applicable as safety data was not planned to be collected during the study</time_frame>
      <desc>Safety data was not planned to be collected during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Apixaban: Naive</title>
          <description>Participants who were treated with apixaban without prior prescription of vitamin K antagonists (VKA) (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date (when the participant took the drug for the first time). The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="E2">
          <title>Apixaban: Non Naive</title>
          <description>Participants who were treated with apixaban with prior prescription of VKA (warfarin or acenocoumarol), dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="E3">
          <title>Acenocoumarol: Naive</title>
          <description>Participants who were treated with acenocoumarol without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="E4">
          <title>Acenocoumarol: Non-Naive</title>
          <description>Participants who were treated with acenocoumarol with prior prescription of different VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="E5">
          <title>Warfarin: Naive</title>
          <description>Participants who were treated with warfarin without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="E6">
          <title>Warfarin: Non Naive</title>
          <description>Participants who were treated with warfarin with prior prescription of different VKA, apixaban, dabigatran or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="E7">
          <title>Dabigatran: Naive</title>
          <description>Participants who were treated with dabigatran without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="E8">
          <title>Dabigatran: Non-Naive</title>
          <description>Participants who were treated with dabigatran with prior prescription of VKA (warfarin or acenocoumarol), apixaban or rivaroxaban in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="E9">
          <title>Rivaroxaban: Naive</title>
          <description>Participants who were treated with rivaroxaban without prior prescription of VKA (warfarin or acenocoumarol), apixaban, dabigatran or rivaroxaban during 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
        <group group_id="E10">
          <title>Rivaroxaban: Non-Naive</title>
          <description>Participants who were treated with rivaroxaban with prior prescription of VKA (warfarin or acenocoumarol), apixaban and dabigatran in the 12 months before start date. The dose and frequency of drug was as per treating physician.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

